According to Cubadebate.cu, successful clinical tests have proven the efficiency of the vaccine which will be commercialized on the island by the name of Cimavax-EGF, thanks to the patient work of researchers from the Molecular Immunology Center in Havana whom are already assessing the use of the same basic medicine in the treatment of other types of cancer.

According to the weekly Trabajadores, Gisela Gonzalez, head of the project, said the medication cannot prevent the disease, but it considerably improves the state of the patients, offer the possibility of turning advanced cancer into a controllable chronic disease while generating antibodies against the unleashing uncontrolled proteins in the cell proliferation processes.

WHO has stressed that lung cancer is one of the most serious illness and one of with major incidence in humans, responsible of high rates of cancer mortality in the world with over 1 million people dead each year.

Among those that are mostly affected by lung cancer are people over 50 years of age with a history of cigarette smoking and the death of 600 000 passive smokers each year.